Corporate strategic investment in digital health at all-time high

Corporate, or "strategic," investors are busy making digital health investments in smaller companies as they seek to fortify their presence in that important space. So far 2014 boasts about 70 deals worth $800 million, easily exceeding last year's total. Deal volume is nearly double that of 2012. Since 2010 strategic players have made 210 deals totaling $2.34 billion. Qualcomm Ventures is the largest strategic investor, followed by Merck Global Health Innovation fund, BlueCross BlueShield Venture Partners and and Google Ventures. Other strategics in digital health: Intel ($INTC), Johnson & Johnson ($JNJ), Dignity Health, Kaiser Permanente, Reed Elsevier and General Electric ($GE). More

Suggested Articles

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.